All patients
Age < 65y (younger) Age > 65y Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) PD-L1 < 1% PD-L1 < 5% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), atezolizumab based treatment vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.83 [0.69; 1.00]
IMvigor-211 (all population), 2018 0.85 [0.73; 0.99]
IMvigor-211 (PDL1>1%), 2018 0.87 [0.72; 1.06]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.63; 1.21]
0.85 [0.77 ; 0.94 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 4 0% 2,641 moderate not evaluable deaths (OS) (extension)detailed results IMvigor-211 (all population), 2018 0.82 [0.71; 0.94]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.64; 1.18]
0.83 [0.73 ; 0.94 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,165 moderate not evaluable progression or deaths (PFS)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.82 [0.70; 0.96]
IMvigor-211 (all population), 2018 0.89 [0.60; 1.32]
IMvigor-211 (PDL1>1%), 2018 0.86 [0.53; 1.39]
IMvigor-211 (PDL1>5%), 2018 1.01 [0.76; 1.35]
0.86 [0.76 ; 0.98 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 4 0% 2,641 moderate not evaluable CRR detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [1.21; 3.17]
1.96 [1.21 ; 3.17 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable DORdetailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.70 [0.46; 1.08]
IMvigor-211 (all population), 2018 0.16 [0.07; 0.35]
IMvigor-211 (PDL1>1%), 2018 0.20 [0.08; 0.50]
IMvigor-211 (PDL1>5%), 2018 0.16 [0.04; 0.55]
0.26 [0.10 ; 0.66 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 4 82% 650 moderate not evaluable objective responses (ORR)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.15 [0.88; 1.51]
IMvigor-211 (all population), 2018 0.99 [0.68; 1.45]
IMvigor-211 (PDL1>1%), 2018 0.95 [0.61; 1.49]
IMvigor-211 (PDL1>5%), 2018 1.07 [0.58; 2.00]
1.07 [0.88 ; 1.29 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018 4 0% 2,641 moderate not evaluable AE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.34 [0.43; 12.83]
IMvigor-211 (all population), 2018 0.38 [0.17; 0.88]
IMvigor-211 (PDL1>5%), 2018 0.67 [0.11; 4.10]
0.69 [0.24 ; 2.02 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 44% 1,971 moderate not evaluable AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.92 [0.63; 1.34]
IMvigor-211 (all population), 2018 0.80 [0.62; 1.04]
IMvigor-211 (PDL1>5%), 2018 1.38 [0.81; 2.33]
0.94 [0.71 ; 1.23 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 38% 1,971 moderate not evaluable AE leading to death (grade 5)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.27 [0.70; 2.27]
IMvigor-211 (all population), 2018 0.91 [0.46; 1.79]
IMvigor-211 (PDL1>5%), 2018 0.73 [0.16; 3.34]
1.06 [0.69 ; 1.63 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 0% 1,971 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.05 [0.79; 1.40]
IMvigor-211 (all population), 2018 0.37 [0.24; 0.57]
IMvigor-211 (PDL1>5%), 2018 0.44 [0.20; 0.99]
0.58 [0.26 ; 1.26 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 88% 1,978 moderate not evaluable SAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.85; 1.46]
IMvigor-211 (all population), 2018 0.92 [0.70; 1.19]
IMvigor-211 (PDL1>5%), 2018 1.79 [1.05; 3.05]
1.14 [0.84 ; 1.54 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 60% 1,971 moderate not evaluable STRAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.33 [0.99; 1.80]
IMvigor-211 (all population), 2018 0.56 [0.40; 0.78]
IMvigor-211 (PDL1>5%), 2018 0.92 [0.48; 1.80]
0.88 [0.48 ; 1.63 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 86% 1,971 moderate not evaluable TRAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.04 [0.53; 2.03]
IMvigor-211 (all population), 2018 0.28 [0.19; 0.40]
IMvigor-211 (PDL1>5%), 2018 0.38 [0.19; 0.79]
0.47 [0.21 ; 1.04 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 83% 1,971 moderate not evaluable TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.02 [0.72; 1.43]
IMvigor-211 (all population), 2018 0.33 [0.25; 0.45]
IMvigor-211 (PDL1>5%), 2018 0.55 [0.31; 0.99]
0.57 [0.27 ; 1.22 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 91% 1,971 moderate not evaluable TRAE leading to death (grade 5)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [0.60; 6.40]
IMvigor-211 (all population), 2018 0.42 [0.13; 1.39]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.14; 7.10]
0.92 [0.34 ; 2.54 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 38% 1,971 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results IMvigor-211 (all population), 2018 0.22 [0.12; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.37 [0.15; 0.92]
0.25 [0.15 ; 0.41 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.67; 1.84]
IMvigor-211 (all population), 2018 0.40 [0.18; 0.89]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.19; 4.97]
0.75 [0.36 ; 1.58 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 56% 1,971 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.00 [0.82; 4.92]
IMvigor-211 (all population), 2018 0.42 [0.18; 0.97]
IMvigor-211 (PDL1>5%), 2018 0.49 [0.04; 5.45]
0.81 [0.24 ; 2.76 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 69% 1,971 moderate not evaluable Constipation TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.02 [0.00; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.12 [0.01; 2.28]
0.05 [0.01 ; 0.38 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.59 [0.27; 25.03]
2.59 [0.27 ; 25.03 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.61 [0.70; 9.73]
IMvigor-211 (all population), 2018 0.37 [0.15; 0.88]
IMvigor-211 (PDL1>5%), 2018 2.00 [0.36; 11.15]
1.12 [0.28 ; 4.54 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 72% 1,971 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.04 [0.00; 0.27]
IMvigor-211 (PDL1>5%), 2018 0.09 [0.01; 1.75]
0.05 [0.01 ; 0.26 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Nausea TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.73 [0.31; 9.49]
1.73 [0.31 ; 9.49 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.01 [1.12; 3.62]
IMvigor-211 (all population), 2018 0.04 [0.01; 0.15]
IMvigor-211 (PDL1>5%), 2018 0.20 [0.04; 0.97]
0.26 [0.02 ; 3.59 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 93% 1,971 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.12 [0.01; 0.95]
IMvigor-211 (PDL1>5%), 2018 0.32 [0.03; 3.14]
0.19 [0.04 ; 0.87 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.72 [0.06; 51.51]
1.72 [0.06 ; 51.51 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Rash TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.86 [0.02; 43.49]
0.86 [0.02 ; 43.49 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.55; 2.26]
1.11 [0.55 ; 2.26 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Anaemia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.08 [0.82; 1.42]
1.08 [0.82 ; 1.42 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Asthenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.43 [0.81; 2.50]
1.43 [0.81 ; 2.50 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Fatigue AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.66 [0.37; 1.17]
0.66 [0.37 ; 1.17 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.76 [0.81; 3.80]
1.76 [0.81 ; 3.80 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Hypertension AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.22 [1.05; 4.68]
2.22 [1.05 ; 4.68 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.74 [0.44; 1.24]
0.74 [0.44 ; 1.24 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Nausea AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.54 [0.23; 1.27]
0.54 [0.23 ; 1.27 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.38 [1.03; 1.84]
1.38 [1.03 ; 1.84 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.25 [0.89; 1.76]
1.25 [0.89 ; 1.76 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Vomiting AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.86 [0.37; 2.00]
0.86 [0.37 ; 2.00 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 12:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866